Literature DB >> 1903064

Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis.

R W James1, A C Hochstrasser, I Borghini, B Martin, D Pometta, D Hochstrasser.   

Abstract

Two peptides, NA1 and NA2, which we previously suggested to be associated with high density lipoproteins (HDLs), have been purified. Polyclonal antibodies against each peptide and a monoclonal antibody against NA2 have been used to further characterize them and their association with HDL. Immunoblotting studies revealed that the peptides form a complex of molecular mass of approximately 80 kd. Agarose gel filtration showed coelution of NA1/NA2 and apolipoprotein (apo) A-I, the structural protein of HDL. This was confirmed by fast protein liquid chromatography, which further indicated that up to 60% of NA1/NA2 was located within the lower density range of the HDL spectrum. Complementary studies with anti-apo A-I immunoaffinity columns provided evidence that at least 40% of NA1/NA2 was associated with HDL, an association easily disrupted by ultracentrifugal manipulation. Finally, partial amino acid sequences showed virtually complete homology with a recently identified protein, SP-40,40, or cytolysis inhibitor. The protein is suggested to have a powerful inhibitory effect on complement-mediated cell lysis. Our results could thus furnish an explanation for the previously observed modulating influence of HDL on complement activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903064     DOI: 10.1161/01.atv.11.3.645

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  15 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Authors:  T Mitsuhashi; Y M Li; S Fishbane; H Vlassara
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.

Authors:  Thomas W Czeczok; Kristen M Stashek; Jessica E Maxwell; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02

Review 4.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

5.  Mapping Atheroprotective Functions and Related Proteins/Lipoproteins in Size Fractionated Human Plasma.

Authors:  Debi K Swertfeger; Hailong Li; Sandra Rebholz; Xiaoting Zhu; Amy S Shah; W Sean Davidson; Long J Lu
Journal:  Mol Cell Proteomics       Date:  2017-02-21       Impact factor: 5.911

6.  Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters.

Authors:  I Hardardóttir; S T Kunitake; A H Moser; W T Doerrler; J H Rapp; C Grünfeld; K R Feingold
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

7.  Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions.

Authors:  D P Witte; B J Aronow; M L Stauderman; W D Stuart; M A Clay; R A Gruppo; S H Jenkins; J A Harmony
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

Review 8.  Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.

Authors:  Peng Xiu; Xiao-Feng Dong; Xin-Ping Li; Jie Li
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

9.  Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis.

Authors:  N H Choi-Miura; T Sakamoto; S Ohtaki; H Nakamura; S Ishizawa; Y Takagi; K Gomi; M Tomita
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

10.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus.

Authors:  L E French; A P Sappino; J Tschopp; J A Schifferli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.